Total trials
75
Active
7
Phase 3
3
Total enrollment
28,082
Pipeline matrix
Showing 4 of 4 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Enavogliflozin 0.3mg | — | — | — | — | — | 1 | |
| LuminoMark inj. 0.2mL | — | — | — | — | — | 1 | |
| SNP array genotyping | — | — | — | — | — | 1 | |
| Baracle Tab.® | — | — | — | — | — | 1 |
Next readouts
- 2026-12-30
- 2026-12-31
- 2027-04-29
- 2028-12-31
Top conditions
- Cholecystitis, Acute3
- Lung Cancer3
- Chronic Myeloid Leukemia3
- Healthy2
- Myelodysplastic Syndrome2
- Coronary Artery Disease2
- Lymphoma2
- Thyroid Cancer2
Frequently asked questions about Seoul St. Mary's Hospital
- How many clinical trials does Seoul St. Mary's Hospital have on ClinicalTrials.gov?
- Seoul St. Mary's Hospital is listed as the lead sponsor on 75 clinical trials in ClinicalTrials.gov, 7 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Seoul St. Mary's Hospital's trials are in Phase 3?
- 3 of Seoul St. Mary's Hospital's trials are in Phase 3, spread across 4 active drug programs.
- What therapeutic areas does Seoul St. Mary's Hospital focus on?
- Seoul St. Mary's Hospital's most-studied conditions on ClinicalTrials.gov are Cholecystitis, Acute, Lung Cancer, Chronic Myeloid Leukemia, Healthy, Myelodysplastic Syndrome.
- When are Seoul St. Mary's Hospital's next clinical trial readouts?
- Seoul St. Mary's Hospital has 4 upcoming primary-completion readouts tracked here; the soonest is “Prediction of Atrial Fibrillation Using Polygenic Risk Score”, expected around 2026-12-30.